Zanidatamab plus palbociclib and fulvestrant in previously treated patients with hormone receptor-positive, HER2-positive metastatic breast cancer: primary results from atwo-part, multicentre, single-arm, phase 2a study

Escrivá-de-Romani, S; Cejalvo, JM; Alba, E; Friedmann, J; Rodríguez-Lescure, A; Savard, MF; Pezo, RC; Gion, M; Ruiz-Borrego, M; Hamilton, E; Pluard, T; Webster, M; Beeram, M; Linden, H; Saura, C; Shpektor, D; Salim, B; Harvey, P; Hurvitz, SA – 2025 –...

Nivolumab plus platinum-doublet chemotherapy in treatment-naive patients with advanced grade 3 Neuroendocrine Neoplasms of gastroenteropancreatic or unknown origin: The multicenter phase 2 NICE-NEC trial (GETNE-T1913) – NATURE COMMUNICATIONS

Riesco-Martinez, MC; Capdevila, J; Alonso, V; Jimenez-Fonseca, P; Teule, A; Grande, E; Sevilla, I; Benavent, M; Alonso-Gordoa, T; Custodio, A; Anton-Pascual, B; Hernando, J; Polo, E; Castillo-Trujillo, OA; Lamas-Paz, A; Teijo, A; Rodriguez-Gil, Y; Soldevilla, B;...

CD8+NKs as a potential biomarker of complete response and survival with lenalidomide plus R-GDP in the R2-GDP-GOTEL trial in recurrent/refractory diffuse large B cell lymphoma – FRONTIERS IN IMMUNOLOGY

Hontecillas-Prieto, L; García-Domínguez, DJ; Palazón-Carrión, N; García-Sancho, AM; Nogales-Fernández, E; Jiménez-Cortegana, C; Sánchez-León, ML; Silva-Romeiro, S; Flores-Campos, R; Carnicero-González, F; Ríos-Herranz, E; de la Cruz-vicente, F; Rodríguez-García, G;...